Evidence map›Paper›PMID 36940016›Full record

ArticleMolecular biotechnology2024

In Silico Analysis of a Candidate Multi-epitope Peptide Vaccine Against Human Brucellosis.

Zahra Yazdani, Alireza Rafiei, Mehrafarin Ghoreyshi, Saeid Abediankenari

Open access · bronzeAbstract read
In one paragraph

Article in Molecular biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Frontiers in pharmacology · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Zahra YazdaniDepartment of Immunology, Molecular and Cell Biology Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.ORCID http://orcid.org/0000-0002-4848-8266
Alireza RafieiDepartment of Immunology, Molecular and Cell Biology Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. rafiei1710@gmail.com.ORCID http://orcid.org/0000-0002-1766-6605
Mehrafarin GhoreyshiStudents Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
Saeid AbediankenariImmunogenetics Research Center, Department of Immunology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.ORCID http://orcid.org/0000-0002-4287-2670
Mazandaran University of Medical Sciences · IR

Funding

Mazandaran University of Medical Sciences 8477
6 · The paper itself

Abstract

Brucellosis is one of the neglected endemic zoonoses in the world. Vaccination appears to be a promising health strategy to prevent it. This study used advanced computational techniques to develop a potent multi-epitope vaccine for human brucellosis. Seven epitopes from four main brucella species that infect humans were selected. They had significant potential to induce cellular and humoral responses. They showed high antigenic ability without the allergenic characteristic. In order to improve its immunogenicity, suitable adjuvants were also added to the structure of the vaccine. The physicochemical and immunological properties of the vaccine were evaluated. Then its two and three-dimensional structure was predicted. The vaccine was docked with toll-like receptor4 to assess its ability to stimulate innate immune responses. For successful expression of the vaccine protein in Escherichia coli, in silico cloning, codon optimization, and mRNA stability were evaluated. The immune simulation was performed to reveal the immune response profile of the vaccine after injection. The designed vaccine showed the high ability to induce immune response, especially cellular responses to human brucellosis. It showed the appropriate physicochemical properties, a high-quality structure, and a high potential for expression in a prokaryotic system.

Indexed as

BrucellaBrucellosisComputer SimulationVaccines, SubunitAntigens, BacterialBrucella VaccineEpitopesEscherichia coliHumansMolecular Docking SimulationProtein Subunit VaccinesToll-Like Receptor 4Antigens, BacterialBrucella VaccineEpitopesProtein Subunit VaccinesToll-Like Receptor 4Vaccines, SubunitHuman brucellosisImmune stimulationIn silicoMulti-epitope peptide vaccineToll-like receptor4

Identifiers

PMID36940016
PMCPMC10026239
OpenAlexW4327892757

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.